Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.

U.S. stock futures and global equities markets tumbled along with the dollar and Treasury yields following the Trump ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...

Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...

FDA grants accelerated approval for Novartis's Vanrafia (atrasentan) for IgA nephropathy. The drug joins Tarpeyo and Filspari ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.

The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that ...